UPC
Universe Pharmaceuticals INC
$5.80
-0.52 (-8.23%)
At close · Jul 8
Market Cap
$3.85M
Shares
631,761
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$17.86B
-22.4%
FY2025
Net Income
-$3.67B
+57.9%
FY2025
Gross Margin
35.28%
+8.9pp
FY2025
Operating Margin
-16.33%
+18.5pp
FY2025
Diluted EPS
-$8.06
+98.7%
FY2025
Operating Cash Flow
-$5.05B
+46.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $17.86B | $23.02B | $32.31B | $40.14M | $47.98M | $30.7M | $33.23M | |
| $11.56B | $16.95B | $21.99B | $18.25M | $22.66M | $16.61M | $19.82M | |
| $6.3B | $6.07B | $10.32B | $21.89M | $25.33M | $14.09M | $13.41M | |
| 35.28% | 26.37% | 31.93% | 54.53% | 52.78% | 45.9% | 40.35% | |
| $671.76M | $3.03B | $4.86B | $7.64M | $5.47M | $583.13K | $618.44K | |
| $3.75B | $2.89B | $2.64B | $2.18M | $3.3M | $1.7M | $1.46M | |
| $43.25M | $11.7M | $5.1M | $5030 | $5523 | $5131 | $5232 | |
| $517.43M | $485.73M | $508.79M | $533.95K | $446.88K | $410.08K | $418.43K | |
| $9.22B | $14.09B | $14.28B | $28.91M | $11.74M | $3.84M | $3.65M | |
| -$2.92B | -$8.02B | -$3.97B | -$7.02M | $13.59M | $10.25M | $9.75M | |
| -16.33% | -34.83% | -12.28% | -17.49% | 28.32% | 33.39% | 29.35% | |
| -$2.4B | -$7.53B | -$3.46B | -$6.49M | $14.04M | $10.66M | $10.17M | |
| $289.39M | $304.52M | $190.18M | $162.4K | $101.6K | $123.76K | $129.27K | |
| -$756.14M | -$100.75M | -$361.33M | -$74.87K | $88.34K | -$151.29K | -$99.77K | |
| $65.06M | $31.94M | $31.07M | $38.59K | $30.83K | $21.82K | $26.74K | |
| -$3.67B | -$8.12B | -$4.33B | -$7.09M | $13.68M | $10.1M | $9.65M | |
| — | $606.7M | $2.25B | $815.32K | $2.36M | $2.54M | $2.1M | |
| -$3.67B | -$8.73B | -$6.58B | -$7.91M | $11.32M | $7.56M | $7.55M | |
| -20.56% | -37.9% | -20.37% | -19.7% | 23.59% | 24.62% | 22.73% | |
| -$4.37B | -$7.47B | -$7.36B | -$11.66M | $12.51M | — | — | |
| USD/shares | -$8.06 | -$626.96 | -$1,089.21 | -$1,309.11 | $2,148.00 | $1,692.00 | — |
| USD/shares | -$8.06 | -$626.96 | -$1,089.21 | -$1,309.11 | $2,148.00 | $1,692.00 | — |
| shares | 455.87K | 13.92K | 6042 | 6042 | 5272.45 | 4444.4444 | 4444.4444 |
| shares | 455.87K | 13.92K | 6042 | 6042 | 5272.45 | 4444.4444 | 4444.4444 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Revenue from Sales of Self-Manufactured TCMD Products | $13,260,650,000 | $14,026,049,000 | $18,572,658,000 |
| Revenue from Sales of Third Party Products | $4,598,082,000 | $8,998,409,000 | $13,736,077,000 |
Key facts
CIK
1809616
CUSIP
G9442G138